649 related articles for article (PubMed ID: 18728033)
41. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
42. Polyunsaturated fatty acids interfere with formation of the immunological synapse.
Geyeregger R; Zeyda M; Zlabinger GJ; Waldhäusl W; Stulnig TM
J Leukoc Biol; 2005 May; 77(5):680-8. PubMed ID: 15703198
[TBL] [Abstract][Full Text] [Related]
43. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
44. Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28.
Molinero LL; Fuertes MB; Rabinovich GA; Fainboim L; Zwirner NW
J Leukoc Biol; 2002 May; 71(5):791-7. PubMed ID: 11994503
[TBL] [Abstract][Full Text] [Related]
45. Characterization of intercellular adhesion molecule-1 (ICAM-1)-augmented degranulation by cytotoxic T cells. ICAM-1 and anti-CD3 must be co-localized for optimal adhesion and stimulation.
Berg NN; Ostergaard HL
J Immunol; 1995 Aug; 155(4):1694-702. PubMed ID: 7636228
[TBL] [Abstract][Full Text] [Related]
46. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
[TBL] [Abstract][Full Text] [Related]
47. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
48. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
[TBL] [Abstract][Full Text] [Related]
49. Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy.
Duarte RF; Chen FE; Lowdell MW; Potter MN; Lamana ML; Prentice HG; Madrigal JA
Gene Ther; 2002 Oct; 9(20):1359-68. PubMed ID: 12365001
[TBL] [Abstract][Full Text] [Related]
50. Anti-leucocyte function-associated antigen-1 antibodies inhibit T-cell activation following low-avidity and adhesion-independent interactions.
Gorochov G; Gross G; Waks T; Eshhar Z
Immunology; 1993 Aug; 79(4):548-55. PubMed ID: 8406579
[TBL] [Abstract][Full Text] [Related]
51. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes.
Malviya G; D'Alessandria C; Bonanno E; Vexler V; Massari R; Trotta C; Scopinaro F; Dierckx R; Signore A
J Nucl Med; 2009 Oct; 50(10):1683-91. PubMed ID: 19759100
[TBL] [Abstract][Full Text] [Related]
52. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
[TBL] [Abstract][Full Text] [Related]
53. The major histocompatibility complex-restricted antigen receptor on T cells. IX. Role of accessory molecules in recognition of antigen plus isolated IA.
Gay D; Coeshott C; Golde W; Kappler J; Marrack P
J Immunol; 1986 Mar; 136(6):2026-32. PubMed ID: 3512708
[TBL] [Abstract][Full Text] [Related]
54. CD3 bright lymphocyte population reveal gammadelta T cells.
Lambert C; Genin C
Cytometry B Clin Cytom; 2004 Sep; 61(1):45-53. PubMed ID: 15351982
[TBL] [Abstract][Full Text] [Related]
55. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
56. CD40 monoclonal antibody activation of antigen-presenting cells improves therapeutic efficacy of tumor-specific T cells.
Bergstrom RT; Silverman DA; Chambers K; Kim JA
Otolaryngol Head Neck Surg; 2004 Jan; 130(1):94-103. PubMed ID: 14726917
[TBL] [Abstract][Full Text] [Related]
57. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
58. Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86.
Habib-Agahi M; Jaberipour M; Phan TT; Searle PF
Iran J Immunol; 2008 Sep; 5(3):136-47. PubMed ID: 18791280
[TBL] [Abstract][Full Text] [Related]
59. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
[TBL] [Abstract][Full Text] [Related]
60. Induction of hyporesponsiveness in human lymphocytes-T despite their expression of both the co-receptor CD28 and its ligand B7.
Friccius H; Siegels-Hübenthal P; Rehbein A; Schlotz E; Pawelec G
Cell Immunol; 1993 Oct; 151(2):283-90. PubMed ID: 7691420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
